Haemonetics Corporation
HAE
$81.35
$0.600.74%
NYSE
| 09/27/2025 | 06/28/2025 | 03/29/2025 | 12/28/2024 | 09/28/2024 | |
|---|---|---|---|---|---|
| Net Income | 35.84% | 42.17% | 42.64% | 2.76% | -3.48% |
| Total Depreciation and Amortization | 6.56% | 14.39% | 22.88% | 25.30% | 18.78% |
| Total Amortization of Deferred Charges | -22.09% | -22.09% | -22.09% | -8.24% | -15.33% |
| Total Other Non-Cash Items | 105.62% | 8.03% | -113.56% | -84.85% | -77.74% |
| Change in Net Operating Assets | 88.22% | 29.01% | -28.36% | -56.52% | -847.97% |
| Cash from Operations | 240.27% | 67.51% | -0.01% | -34.48% | -67.61% |
| Capital Expenditure | -115.80% | -9.55% | -3.02% | 30.07% | 59.34% |
| Sale of Property, Plant, and Equipment | -85.45% | -85.36% | 1,184.70% | 542.27% | 528.12% |
| Cash Acquisitions | 100.00% | 99.55% | 38.12% | 38.12% | -- |
| Divestitures | 2,786.07% | 2,786.07% | 2,786.07% | -- | -- |
| Other Investing Activities | -14.37% | -48.43% | 12.50% | 1.93% | -75.64% |
| Cash from Investing | 85.87% | 87.52% | 49.78% | 41.04% | -368.44% |
| Total Debt Issued | -100.00% | -100.00% | 763.64% | 763.64% | -- |
| Total Debt Repaid | 98.90% | 112.69% | -595.76% | -5,277.38% | -864.36% |
| Issuance of Common Stock | 0.05% | -3.07% | 15.51% | 14.20% | 19.43% |
| Repurchase of Common Stock | -171.40% | -1,527.15% | -3,897.33% | -1,348.48% | -1,352.19% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 99.77% | -280.22% | -12,002.39% | -13,418.77% | -12,437.91% |
| Cash from Financing | -175.15% | -161.03% | 185.18% | 96.66% | 616.17% |
| Foreign Exchange rate Adjustments | -101.07% | 286.07% | 78.49% | -27,881.82% | 101.90% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 94.48% | -187.77% | 221.10% | 522.56% | -147.10% |